[144] Health Catalyst, Inc SEC Filing

Rhea-AI Filing Summary

Health Catalyst, Inc. (HCAT) Form 144 notice reports a proposed sale of 2,854 common shares with an aggregate market value of $9,597.15, to be sold through Morgan Stanley Smith Barney LLC on 09/02/2025 on NASDAQ. The shares were acquired on 09/02/2025 as restricted stock from Health Catalyst, Inc. and were granted as compensation. The filer represents they are not aware of undisclosed material adverse information. The filing also discloses a prior sale by Linda Llewelyn of 2,965 restricted shares on 06/02/2025 for gross proceeds of $10,777.18.

Positive

• Filer provided required Rule 144 details: class, quantity, broker, exchange, acquisition date, and nature of acquisition (compensation).
• Planned sale routed through a registered broker (Morgan Stanley Smith Barney LLC) and lists NASDAQ as the market.

Negative

• Insider sold restricted shares recently: 2,965 shares sold on 06/02/2025 for gross proceeds of $10,777.18, which is disclosed in the filing.

Insights

Securities Compliance Analyst

TL;DR Form 144 notifies a planned Rule 144 sale of 2,854 restricted shares acquired as compensation; filing appears procedural and compliant.

The filing documents a proposed sale under Rule 144 through a registered broker, names the broker and exchange, and states acquisition and payment details explicitly: restricted stock acquired and paid as compensation on the same date listed. It includes a recent related sale by the same person in June 2025. From a compliance perspective, the submission contains the core elements required for a Rule 144 notice: class, quantity, acquisition details, sale timing, broker, and a representation about undisclosed material information.

Equity Transactions Specialist

TL;DR Transaction size is modest and routine; filing signals a planned insider disposition via broker on NASDAQ.

The notice shows a small, single-party disposition (2,854 shares, ~$9.6k) to be executed on a specified date via Morgan Stanley Smith Barney. The shares were acquired as restricted compensation on the same date listed and are being sold under Rule 144. A prior sale of 2,965 restricted shares generated ~$10.8k in June 2025. The amounts disclosed are small in absolute terms relative to typical public-company float, suggesting limited market impact; all material transaction details are provided in the form.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC 1 New York Plaza, 38th Floor New York NY 10004	2854	9597.15	70373625	09/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/02/2025	Restricted Stock	Health Catalyst, Inc.			2854	09/02/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Linda Llewelyn c/o 10897 South River From Parkway #300 South Jordan UT 84095	Restricted Stock	06/02/2025	2965	10777.18

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for HCAT disclose?

The Form 144 discloses a proposed sale of 2,854 common shares (aggregate market value $9,597.15) to be sold via Morgan Stanley Smith Barney on 09/02/2025 on NASDAQ.

How were the 2,854 HCAT shares acquired?

The filing states the shares were acquired on 09/02/2025 as restricted stock from Health Catalyst, Inc., with the payment characterized as compensation.

Did the filer sell any HCAT shares recently?

Yes. The filing reports a prior sale by Linda Llewelyn of 2,965 restricted shares on 06/02/2025 for gross proceeds of $10,777.18.

Which broker and exchange are involved in the proposed sale?

The proposed sale names Morgan Stanley Smith Barney LLC as the broker and NASDAQ as the exchange.

Does the filer attest to possession of material nonpublic information?

Yes. By signing the notice, the person represents they do not know of any material adverse information about the issuer that has not been publicly disclosed.